Alluvi, previously BI 4744, represents a significant advance in obesity treatment. This dual agonist targeting both GLP-1 and GIP targets demonstrates remarkable results in patient assessments, potentially surpassing https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/